07:59 AM EDT, 03/11/2024 (MT Newswires) -- Microbix Biosystems Inc. ( MBXBF ) , in the life sciences industry, on Monday said it is presenting results of Quality Assessment Products (QAPs) for supporting the quality control (QC) of histology and PCR-based tests driven by tissue-samples of Head and Neck cancer caused by human papilloma virus (HPV).

Its results presentation will be made at EUROGIN 2024, an international collaborative conference and exhibition focused upon innovations in HPV research and global cancer solutions taking place in Stockholm, Sweden from March 13 to 16.

While HPV is best known for causing cancers of the cervix in women, this virus family also causes cancer in other bodily tissues. Unfortunately, a lack of standardized and reproducible reference samples makes it challenging to control the recommended test workflows for diagnosing head and neck cancers. Microbix and collaborators at Sunnybrook Health Sciences Centre and Dartmouth-Hitchcock Medical Center worked to address this need. Microbix developed homogenous and reproducible simulated-specimen paraffin blocks to monitor the accuracy and reliability of such testing, which is being presented via a poster.

Microbix will now work to optimize its tissue scaffold designs for supporting both histology and PCR workflows. These standardized and reproducible tissue-oriented test controls will then be added to Microbix's catalogue of QAPs, expanding its activities into support of oncology workflows alongside its wide range of infectious disease test controls.